Regeneron Pharmaceuticals traded at $660.66 this Tuesday July 14th, decreasing $2.43 or 0.37 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals lost 7.43 percent. Over the last 12 months, its price rose by 20.57 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 650.63 by the end of this quarter and at 610.68 in one year, according to Trading Economics global macro models projections and analysts expectations.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.